S
Sachet A. Shukla
Researcher at Harvard University
Publications - 97
Citations - 44497
Sachet A. Shukla is an academic researcher from Harvard University. The author has contributed to research in topics: Antigen & Human leukocyte antigen. The author has an hindex of 39, co-authored 89 publications receiving 34805 citations. Previous affiliations of Sachet A. Shukla include Massachusetts Institute of Technology & Broad Institute.
Papers
More filters
Journal ArticleDOI
Comprehensive metabolomic profiling of plasma from patients (pts) with metastatic urothelial carcinoma (mUC) receiving immune checkpoint inhibitors (ICI) or platinum-based chemotherapy (PBC).
Talal El Zarif,Elio Adib,C. Clish,Sachet A. Shukla,Dory Freeman,Jonathan David Thomas,Praful Ravi,Martha Tuff,Bradley Alexander McGregor,Charlene Mantia,Arvind Ravi,Guru Sonpavde +11 more
TL;DR: This is the first report, to the authors' knowledge, of comprehensive metabolomic plasma profiling of pre- and post-ICI and PBC pts with mUC, and the metabolomic changes after ICI appear distinct from those seen after PBC.
Proceedings ArticleDOI
Abstract 999: The genomic landscape of pediatric Ewing sarcoma
Brian D. Crompton,Chip Stewart,Amaro Taylor-Weiner,Gabriela Alexa,Kyle C. Kurek,Monica L. Calicchio,Adam Kiezun,Scott L. Carter,Sachet A. Shukla,Swapnil Mehta,Aaron R. Thorner,Carmen de Torres,Cinzia Lavarino,Mariona Suñol,Aaron McKenna,Andrey Sivachenko,Kristian Cibulskis,Michael S. Lawrence,Lauren Ambrogio,Daniel Auclair,Ivan Imaz Rosshandler,Angela Schwarz-Cruz y Celis,Miguel Rivera,Carlos Rodriguez-Galindo,Mark D. Fleming,Todd R. Golub,Gad Getz,Jaume Mora,Kimberly Stegmaier +28 more
TL;DR: Crompton et al. as mentioned in this paper performed whole-exome sequencing of 96 Ewing sarcoma tumors and 11 Ewing SARcoma cell lines, as well as whole-genome sequencing, transcriptome sequencing and copy-number analysis of a subset of these samples.
Proceedings ArticleDOI
Abstract 1093: Sensitive detection of somatic mutations in class I HLA genes reveals enrichment for functional events in cancer
Sachet A. Shukla,Mohini Rajasagi,Philip M. Dixon,Grace Tiao,Michael S. Lawrence,Carrie Sougnez,Vladimir Brusic,Kristian Cibulskis,Adam Kiezun,Catherine J. Wu,Gad Getz +10 more
Journal ArticleDOI
Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade.
David A. Braun,Yue Hou,Ziad Bakouny,Miriam Ficial,Miriam Sant'Angelo,Petra Ross-Macdonald,Opeyemi Jegede,Maxine Sun,Megan Wind-Rotolo,Jean-Christophe Pignon,Donna Neuberg,Paul J. Catalano,Gordon J. Freeman,Arlene H. Sharpe,David F. McDermott,Eliezer M. Van Allen,Sabina Signoretti,Catherine J. Wu,Sachet A. Shukla,Toni K. Choueiri +19 more
TL;DR: This data indicates that suppression of the PD-1 pathway through ‘cell reprograming’ may be a viable strategy for the treatment of renal cell carcinoma by utilizing a second checkpoint pathway, called ‘clinically checkpoints’, which are currently out of use in clinical practice.